Inhibition of macrophage-related IL-6 trans-signaling with soluble glycoprotein 130 Fc fusion protein (sgp130Fc), an innovative therapeutic biomacromolecular drug that specifically targets IL-6 trans-signaling, enhances AECII survival and promotes lung growth in experimental BPD (17) (Figure 2). This evidence concerns the gene IL6 and bronchopulmonary dysplasia.